AI news

Isomorphic Labs announces $5B Series C for drug design and clinical preparation

By 杨京丽0 viewsSource: 智东西
Isomorphic Labs drug design and clinical development

Isomorphic Labs says its November 17 Series C was co-led by Greenoaks and Sequoia Capital. Funds will support IsoDDE, drug candidates and R&D infrastructure. Reported positive results are largely preclinical; human safety and efficacy still need validation.

Article illustration

Total funding of 51.3 billion yuan.

Zhidx reported on November 17 that Isomorphic Labs, the British AI drug-development company founded by Nobel laureate and Google DeepMind co-founder Demis Hassabis, had just announced $5 billion in Series C funding, approximately 33.3 billion yuan, in an oversubscribed round.

Based on an incomplete tally of public data, this round surpassed the company's previous single-round fundraising record and may have set a new global record for a single funding round in AI drug development.

Article illustration

▲Hassabis announces Isomorphic Labs' Series C funding. Image: X.

In March 2025, Isomorphic Labs announced $600 million, approximately 4 billion yuan, in its first external funding round. This May, it raised another $2.1 billion, approximately 14 billion yuan in a Series B, then a global single-round fundraising record for the AI pharmaceutical industry. Including the latest Series C, Isomorphic Labs' publicly disclosed funding totals $7.7 billion, approximately 51.3 billion yuan.

The round was co-led by Greenoaks and Sequoia Capital, with participation from a16z and several new investors, while Alphabet continued to invest substantially. All existing investors also participated, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK's Sovereign AI Fund.

Founded in 2021 and headquartered in London, Isomorphic Labs focuses on using AI to design and develop new medicines. It plans to use the new capital to upgrade its proprietary drug-design engine, IsoDDE, expand its internal and partnered drug-candidate pipelines, and build global AI-driven bioengineering infrastructure. The company says its internal oncology and immunology programs, as well as partnered programs, have produced positive preclinical results and are being prepared for clinical trials.

01.

Founded by a Google DeepMind co-founder

Focused on AI drug design

Incubated by Google DeepMind, Isomorphic Labs is an AI drug-development company within Google's parent Alphabet, operating and raising external funding independently. It is led by founder and CEO Demis Hassabis and president Max Jaderberg.

Hassabis is a co-founder and chairman of Google DeepMind and Alphabet's chief scientist. He received the 2024 Nobel Prize in Chemistry for AlphaFold's work on protein-structure prediction.

Article illustration

▲Isomorphic Labs founder and CEO Demis Hassabis.

Jaderberg holds a PhD from the University of Oxford and previously led DeepMind's open-ended learning research team. A founding team member of Isomorphic Labs, he served as chief AI officer, leading development of its drug-design engine and models such as AlphaFold 3, before becoming president in January 2026.

Hassabis said that when Isomorphic Labs was founded, the team believed biology could be understood and modeled at its most fundamental molecular level, and that AI could dramatically accelerate the process.

He also said Isomorphic Labs' drug-design engine was generating molecules with greater precision and speed. The new funding would help the team move faster in building foundational biology models, deepening understanding of systemic disease mechanisms and advancing its first therapeutic programs toward clinical trials.

02.

An AI drug-design engine spanning multiple therapeutic areas

Advancing different types of drug development

Isomorphic Labs' core technology is its proprietary drug-design engine, IsoDDE. The engine integrates a suite of foundational AI simulation models spanning multiple therapeutic areas and drug modalities.

IsoDDE can explore vast chemical spaces to help R&D teams design, optimize and select molecules with desirable drug-like properties. Isomorphic Labs says these simulation models are bringing predictions closer to experimental accuracy, providing additional capabilities for innovative drug development.

Beyond simulation models, Isomorphic Labs has developed proprietary agents to explore and reason about complex biological systems. The company says its combined models and agents have consistently advanced pipelines across multiple drug modalities. Its internal oncology and immunology programs and partnered programs have produced positive preclinical results, laying the groundwork for entering clinical development.

Isomorphic Labs president Jaderberg says the team makes reproducible scientific progress with its models every week and translates it into improved molecular properties, with the potential to develop those molecules into new drugs. Its interdisciplinary team brings together machine-learning researchers and drug-development specialists to tackle complex biological problems that have remained unresolved for decades.

Following the round, Isomorphic Labs will continue refining IsoDDE and use more advanced models to explore new areas of biology.

The company also plans to build a partner ecosystem and deepen understanding of disease mechanisms to support the development of new classes of therapeutics. Meanwhile, it will build global bioengineering infrastructure and scalable, AI-centered translational-research and clinical-development systems to support drug candidates entering clinical trials.

03.

After the major funding round:

Clinical validation becomes crucial

The intended uses of this funding extend beyond model research into drug pipelines, translational research and clinical-development infrastructure. For Isomorphic Labs, a major task in the next stage is turning computational prediction and molecular-design capabilities into drug candidates ready to enter the clinic.

Most of Isomorphic Labs' main results remain at the preclinical stage. As its first programs move toward clinical trials, the safety, efficacy and development progress of its drug candidates will become important evidence for assessing AI drug-design capabilities.

Sources: Isomorphic Labs, X.

This article was originally published by Zhidx. Author: Yang Jingli.

Related topics

After reading

Join the AINRK community

Read how to join the community and connect with people working in AI.

Community information (opens in a new tab)